Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective
Autor: | Simon Naseri, Lisbet Rosenkrantz Hölmich, Niels Junker, Seppo W. Langer, Torben Steiniche, Morten Ladekarl, Alessandro Venzo, Marie Louise Bønnelykke-Behrndtz, Mathilde S. Larsen, Elizaveta Mitkina Tabaksblat, Annette H. Chakera, Siri Klausen |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty diagnosis medicine.medical_treatment review Review Disease Guideline lcsh:RC254-282 merkel cell carcinoma 030207 dermatology & venereal diseases 03 medical and health sciences Merkel cell carcinoma 0302 clinical medicine Internal medicine Diagnosis medicine Lymph node Chemotherapy treatment business.industry Incidence (epidemiology) lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Treatment Clinical trial medicine.anatomical_structure 030220 oncology & carcinogenesis Localized disease business guideline |
Zdroj: | Naseri, S, Steiniche, T, Ladekarl, M, Bønnelykke-Behrndtz, M L, Hölmich, L R, Langer, S W, Venzo, A, Tabaksblat, E, Klausen, S, Skaarup Larsen, M, Junker, N & Chakera, A H 2020, ' Management Recommendations for Merkel Cell Carcinoma-A Danish Perspective ', Cancers, vol. 12, no. 3, 554 . https://doi.org/10.3390/cancers12030554 Cancers, Vol 12, Iss 3, p 554 (2020) Naseri, S, Steiniche, T, Ladekarl, M, Bønnelykke-Behrndtz, M L, Hölmich, L R, Langer, S W, Venzo, A, Tabaksblat, E, Klausen, S, Larsen, M S, Junker, N & Chakera, A H 2020, ' Management recommendations for merkel cell carcinoma : a Danish perspective ', Cancers, vol. 12, no. 3, 554 . https://doi.org/10.3390/cancers12030554 Cancers Naseri, S, Steiniche, T, Ladekarl, M, Bønnelykke-Behrndtz, M L, Hölmich, L R, Langer, S W, Venzo, A, Tabaksblat, E, Klausen, S, Larsen, M S, Junker, N & Chakera, A H 2020, ' Management Recommendations for Merkel Cell Carcinoma : A Danish Perspective ', Cancers, vol. 12, no. 3, 554 . https://doi.org/10.3390/cancers12030554 |
ISSN: | 2072-6694 |
Popis: | Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine carcinoma of the skin with a poor prognosis and an apparent increase in incidence. Due to its rarity, evidence-based guidelines are limited, and there is a lack of awareness among clinicians. This review constitutes the consensus management recommendations developed by the Danish MCC expert group and is based on a systematic literature search. Patients with localized disease are recommended surgical excision and adjuvant radiotherapy to the primary site; however, this may be omitted in patients with MCC with low risk features. Patients with regional lymph node involvement are recommended complete lymph node removal and adjuvant radiotherapy in case of extracapsular disease. Metastatic disease was traditionally treated with chemotherapy, however, recent clinical trials with immune therapy have been promising. Immune checkpoint inhibitors targeting the programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1) axis should therefore be strongly considered as first-line treatment for fit patients. A 5-year follow-up period is recommended involving clinical exam every 3 months for 2 years and every 6 months for the following 3 years and PET-CT one to two times a year or if clinically indicated. These national recommendations are intended to offer uniform patient treatment and hopefully improve prognosis. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |